We have previously reported the construction of a cell cycle-regulated HSV-1 amplicon vector (denoted as pC8-36) that confers luciferase reporter gene activities dependent on cellular divisions. However, luciferase reporter gene is well known for its relatively high sensitivity, thus, it is crucial to evaluate the therapeutic efficacy of a transcriptional targeted vector. In this report, we have engineered the FasL and FADD genes into pC8-36 and demonstrated their efficacy for the treatment of human gliomas in vitro and in vivo. Using trypan blue dye exclusion and TUNEL assay, FasL expression mediated by pC8-36 was shown to induce a significantly higher percentage of cell death in proliferating cells than those observed in the G 1 -arrested cells. The observed cell killing effect correlated well with the level of FasL protein expression when analyzed by ELISA assay. Furthermore, the incorporation of both FasL and FADD into pC8-36 resulted in the enhancement of apoptosis in the target glioma cells both in vitro and in vivo. Targeting proliferating tumor cells via the transcriptional control of therapeutic genes could potentially improve the safety and efficacy of cancer gene therapy, and thus would allow the development of strategies for more effective anticancer therapies.
Introduction
Gene therapy faces the same hurdles as traditional drug therapy with respect to specificity, efficacies and potential immune responses. Nevertheless, progress has been made and some day it may prove to be a powerful modality in treating a wide range of human diseases, including cancer. For this approach to attain its potential, it will be necessary to develop a means of precisely targeting the site of disease; also, the vector should be relatively nonimmunogenic. We have previously reported that when all the cell cycle-specific regulatory elements are incorporated in cis into a single Herpes Simplex Virus Type 1 (HSV-1) amplicon plasmid vector backbone (denoted as pC8-36), the reporter luciferase activity can be mediated in a cell cycle-dependent manner in many well-established tumor cell lines (such as Gli36, HeLa, PC-3) and in vivo. Thus, these vectors could potentially represent advantageous tools for cancer gene therapy since most malignant cancer cells are, in general, highly proliferating. In the present study, the efficacy of the vector system is evaluated using apoptosis-inducing genes (FasL-and Fas-Associated protein with a Death Domain, also known as FADD), both in vitro and in vivo. In addition, considering that tumor cells may potentially exhibit differential sensitivity towards FasL expression, we have also explored whether the combined effect of FasL and FADD overexpression would be more effective compared to a single modality alone.
Fas ligand/APO-1L (CD95L) is a 40 kDa type II membrane protein belonging to the tumor necrosis factor (TNF) family. 2, 3 The expression of FasL is very specific; in vivo, FasL is only expressed by cytotoxic T cells, natural killer cells, and in immune privilege sites, for instance, the retina. 4 The FasL receptor, Fas/APO-1 (CD95/ TNFRSF6), is a type I transmembrane protein of the TNF superfamily of receptors. 4 Following engagement with FasL, Fas initiates downstream apoptotic signals in Fas-bearing cells, leading to the activation of the caspase cascade and apoptosis. 4, 5 Crosslinking of Fas with antiFas antibody has been shown to induce apoptosis in human glioma cell lines. 6, 7 However, tumors with low or undetectable level of Fas expression are found to be resistant to FasL-induced cell death. 6 In addition, tumors that have dysfunctional death-inducing signaling complex (DISC), arising from a low level of FADD and/or caspase 8, were also found to be resistant to FasL-induced cell death. 8 Interestingly, it has been reported that overexpression of FADD is able to induce apoptosis in FasL-insensitive cells. [9] [10] [11] [12] Since cancerous cells such as gliomas are known to be highly heterogeneous, it is likely that different clonal populations within a tumor mass might respond differently to different therapeutic agents. Thus, from a therapeutic point of view, the administration of multiple therapeutic agents would be of great benefit.
The strategy adopted in our study is based on a transcriptional repressor protein termed cell cycle-dependent factor 1 (CDF-1), which is specifically expressed during the G 1 -phase and interacts with the cell cycledependent element (CDE) and the cell cycle homology region (CHR) located within the cyclin A promoter. 13 In brief, the transactivation of cyclin A promoter via an interaction of Gal4/NF-YA fusion protein to the Gal4-binding sites is prevented by the recruitment of CDF-1 repressor protein to cyclin A promoter in quiescent cells. In actively proliferating cells, the Gal4/NF-YA fusion protein can transactivate cyclin A promoter and drive the transcription of the reporter or therapeutic gene due to the absence of the CDF-1. The HSV-1-based amplicon vectors have been chosen as the backbone vector for the incorporation of these cell cycle-regulatory elements for two main reasons. Firstly, their large DNA insert capacities of B153 kb are considered ideal for carrying multiple therapeutic transgene cassettes and accommodate transcriptional controlling elements that may prove critical for ensuring prolonged and regulated transgene expression. Secondly, they can be easily packaged into replication defective but infectious amplicon virions using an improved helper virus-free packaging system.
14 Using this technique, helper virus-free amplicon vectors elicited minimal cytotoxicity due to their lack of viral proteins. 15 Thus, HSV-1 amplicon vectors would be ideal for the purpose of transcriptional targeting to cancerous cells.
In this study, we have demonstrated that the level of cell death induced by either FADD or FasL expression mediated by the pC8-36 vectors was B18-37% higher (Po0.05) in actively proliferating cells compared to G 1 -arrested cells when examined by trypan blue exclusion assay. Using ELISA, the upregulation of FasL and FADD proteins expression was confirmed to be 6-to 14-fold higher than the G 1 -arrested cells. Finally, we show that the combined treatment of FasL and FADD enhances tumor glioma cells killing, thus suggesting the possibility that overexpression of FADD protein could enhance the efficacy of FasL.
Materials and methods
Cell culture dGli36 human glioma cells, which overexpress a truncated mutant EGFR commonly found in human gliomas, were kindly provided by Dr M Sena-Esteves (Children's Hospital of Philadelphia, Philadelphia, PA). dGli36 cells were cultured in complete DMEM supplemented with puromycin (1 mg/ml; Sigma-Aldrich Corp., St Louis, MO). The dGli36-SCID8 cells are a clonal derivative of dGli36 cells. This clone was derived from dGli36 tumor harvested from immunodeficient SCID mice and was determined to consistently form a subcutaneous tumor in all SCID mice. When 1 Â 10 6 of dGli36-SCID8 cells were intracranially implanted into immunoincompetent mice, the animals died within 10 days, three times faster than with its parental Gli36 cells. The African green monkey kidney 2-2 cells, which are VERO-derived cells that constitutively express the HSV-1 ICP27 proteins (kindly provided by Dr R Sandri-Goldin, UCLA), were cultivated in the presence of Geniticin (500 mg/ml; Invitrogen Life Technologies, Grand Island, NY). All cells were maintained at 371C in a humidified incubator with 5% CO 2 .
Plasmid constructs
The pORF-hFasL plasmid was purchased from Invivogen (San Diego, CA); the hFasL (B1 kb) was subcloned into pHGCX plasmids 1 using NheI and EcoRV cloning sites. hFasL was reamplified by PCR using pHGCX-FasL plasmid as a template (the forward and reverse primers were FasLF; 5 0 -CCCAAGCTTGGGGCCATGCAGCA GCCC-3 0 and FasLR. 5 0 -CCGGGATCCCGCTCGG TGCCTGTAAC-3 0 , respectively). The amplified DNA fragment was subcloned into the HindIII and XbaI restriction enzyme sites of 8GalcycA plasmid (obtained from R Mu¨ller, Institute of Molecular Biology and Tumor Research, Germany). The 8GalcycAFasL DNA fragment was released from the plasmid 8GalcycA and subcloned into the NheI and BamHI restriction enzyme sites of pHGCX amplicon vector and the pre-existing CMV promoter was subsequently removed using SpeI and NheI to generate pIH8GalFasL plasmid. To construct pC8-FasL, the FasL fragment was amplified by PCR using pHGCX-CMV-FasL plasmid as a template (the forward and reverse primers were FasLF: 5 0 -CCC AAGCTTGGGGCCATGCAGCAGCCC-3 0 and FasLR: 5 0 -CCGGGATCCCGCTCGGTGCCTGTAAC-3 0 , respectively). The 8GalcycAFasL fragment was amplified by PCR using 8GalcycA plasmid as a template (the forward and reverse primers were 8GalF: 5 0 -CCTCTTCGCTATT ACGCC and 8GalR: 5 0 -AAGAAGACAGTCATAAGT GCGG, respectively). The amplified DNA fragment were subcloned into the shuttle plasmid pGemT-easy (Promega, Madison, WI), released using NotI restriction enzyme sites and inserted into pHGCX.GN, 1 thus generating pC8-FasL. For the construction of pIH8GalFADD and pC8-FADD amplicon plasmid, the human FADD cDNA fragment were PCR amplified from pCIneo-FADD (from MV Clement, National University of Singapore, Singapore) using the primers FADD-ORF-F and FADD-ORF-R, followed by subcloning into the HindIII and XbaI restriction enzyme sites of 8GalcycA plasmid. Subsequent cloning procedures were similar to the construction of pC8-FasL amplicon plasmid vector. All plasmids were amplified in STBL-2 (Invitrogen Life Technologies) and DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen GmbH, Hilden, Germany). All plasmids were verified by DNA sequencing (Applied Biosystem Inc.).
Synchronization of cells and cell cycle analysis
For synchronization at G 1 , cells were washed twice with PBS followed by addition of 50 mM of lovastatin (Merck, Singapore) in fresh medium containing 1% fetal bovine serum (FBS). After 48 h, cells were harvested by trypsinization and resuspended in 500 ml of cold 70% ethanol. After an overnight fixation at 41C, cells were washed with PBS thrice, before resuspending in 100 ml of PBS containing 2 mg/ml RNase A (Sigma-Aldrich) and 100 mg/ml propidium iodide (Sigma-Aldrich). The triplicate samples were kept on ice for an hour before FACS analysis was performed using Cell Quest and Modfit software (BD Biosciences, San Jose, CA).
Helper virus-free packaging and amplicon vector transduction Packaging of HSV-1 amplicons into HSV-1 virions was performed as described previously.
14 Briefly, 2-2 cells (3 Â 10 6 cells) were cotransfected with 1.8 mg of amplicon DNA, 0.3 mg pEBHICP27 (a plasmid expressing ICP27) and 3 mg of fHSVDpacD27 using the LipofectAMINE Plus procedure (Invitrogen Life Technologies). At 60 h post-transfection, the cells were scraped into the medium; the suspension was frozen and thawed three times and sonicated for 17 s at 3.5 setting (550 Sonic Dismembrator) and cellular debris was removed by centrifugation for 10 min at 2000 g. The filtrate was then concentrated and purified by centrifugation through 25% sucrose gradient and centrifuged in a Beckman (Fullerton, CA) SW28 rotor at 25 000 r.p.m. for 4 h at 41C. The concentrated vector was resuspended overnight in Hanks' Balance Salt Solution (HBSS) (Invitrogen) and stored in 100 ml aliquots at À801C. To determine vector titers (Transduction unit (TU) per ml), 2-2 cells were infected and 24 h later green fluorescent cells were counted using a fluorescence microscope. For vector transduction, 3 Â 10 5 dGli36 cells per 60-mm well in triplicate were incubated for 6 h at 371C with various amplicon viral vector stocks to achieve a constant multiplicity of infection (MOI). At the end of 6 h, cells were washed twice and fresh medium containing 10% FBS was added to proliferating cells. Synchronization of cells was performed as described above.
Assay for FasL protein expression
To assay for the expression of FasL, cellular extracts and supernatant were harvested separately from 24-well plates at the respective time points following infection. The supernatant was filtered through a 0.22 mm filter followed by concentrating with Centricon (Amicon, MA) with 10 kDa cutoff. To harvest cellular extracts, the cell monolayer was rinsed twice with PBS followed by centrifugation at 2000 g for 5 min. The pellet was lysed in lysis buffer containing 50 mM Tris-Cl (pH 8.0), 0.1% Triton X-100 and 0.1 mM NaCl for 10 min at 41C. Following removal of cellular debris, the supernatant was collected and 1 ml was used for the determination of protein concentration. FasL protein expression was determined using ELISA (Oncogene Research Products, San Diego, CA) according to the manufacturer's instructions.
Assay for FADD protein expression
Cells were harvested from 24-well plates at the respective time point following infection. The cell monolayer was rinsed twice with PBS followed by centrifugation at 2000 g for 5 min. The pellet was lysed in lysis buffer containing 50 mM Tris-Cl (pH 8.0), 0.1 % Triton X-100 and 0.1 mM NaCl for 10 min at 41C. Following removal of cellular debris, the supernatant was collected and 1 ml was used for the determination of protein concentration. For the detection of FADD protein expression, the sandwich ELISA method was adopted. Mouse anti-FADD monoclonal antibody (0.25 mg/ml; Zymed, South San Francisco, CA) was coated on a flat-bottom 96-well plate (Nunc, Roskilde, Denmark) and incubated at 41C overnight. Excess antibody was removed by rinsing thrice in washing buffer containing PBS with 0.1% Tween-20 (Invitrogen Life Technologies). All subsequent washing steps were carried out at room temperature. The coated wells were incubated in blocking buffer (0.1% Tween-20 and 1% BSA (Sigma-Aldrich) in PBS) for 1 h at room temperature. Cell lysates (0.1 mg/ml) were added to each well and incubated at room temperature for 1 h, followed by three rounds of rinsing in washing buffer. Rabbit anti-FADD polyclonal antibodies (Roche Diagnostics GmbH, Mannheim, Germany) were diluted in blocking buffer (2 mg/ ml) and added to each well. After rinsing for five rounds in washing buffer, wells were incubated with HRPconjugated goat anti-rabbit antibody (diluted to a final concentration of 2 mg/ml in blocking buffer) for 30 min, followed by incubation in detection reagent (R&D Systems Inc., Minneapolis, MN) for additional 30 min. Colorimetric development was terminated by the addition of stop buffer containing 2 N sulfuric acid (R&D Systems Inc.). Absorbance reading was analyzed at a wavelength of 450 nm using Spectrafluor Plus (Tecan USA Inc., Research Triangle Park, NC).
Cell viability assay
To determine the viability of cells following infection, the monolayer of infected cells was rinsed with PBS and harvested at the respective time points postinfection. An equal volume of cell suspension was mixed with 0.4% of trypan blue solution (Sigma-Aldrich). Cells were visualized under phase contrast microscope (Nikon). Living cells with intact cellular membrane excluded trypan blue and appeared as highly reflective cells under the microscope. Assays were performed in triplicate. The number of viable cells was expressed as a percentage of the total cells.
Terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) assay dGli36 (3 Â 10 5 ) was plated on coverslips followed by infection with pC8-FasL or pC8-FADD (MOI of 1.0) for 6 h. The cells were then replenished with fresh medium containing 10% FBS or medium supplemented with 50 mM lovastatin. TUNEL staining of apoptotic cells was performed according to the manufacturer's protocol (Roche Diagnostics GmbH). Briefly, after 72 h, cells were rinsed with PBS twice, followed by fixation using 4% paraformaldehyde at room temperature for 1 h. Excess fixative was removed by rinsing in PBS, followed by treatment with PBS containing 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice to permeabilize the cells. After washing with PBS to remove excess permeabilizing solution, cells were incubated in TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (TdT) and TMR red-labeled dUTP, which preferentially label DNA strand breaks generated during apoptosis, for 1 h at 371C. The excess reaction mixture was removed by rinsing in PBS, followed by visualization using a fluorescent microscope (Nikon) with appropriate filters.
Real-time RT-PCR analysis
Total RNA was isolated from tumor mass using TRIzol (Invitrogen Life Technologies) method according to the manufacturer's conditions. For first strand cDNA synthesis1 mg of total RNA was used. cDNA was synthesized using random hexanucleotide primers (Invitrogen Life Technologies) and oligo-dT [12] [13] [14] [15] [16] [17] primers, in the presence of superscript II reverse transcriptase (Invitrogen Life Technologies). The expression level of FasL, FADD and the 18S rRNA was quantitated using QuantiTecht SYBR Green PCR kit (Qiagen). The primer sequences for the amplification of FasL cDNA consisted of FasL-F376-392 (5 0 -GGGCCTGGGGATGTTTC-3 0 ) and FasL-R505-488 (5 0 -TTTTTCAGGGGGTGGACT-3 0 ), whereas primers for amplifying FADD cDNA were FADD-F271-287 (5 0 -GCGCCTGGGGAAGAAGA-3 0 ) and FADD-R414-396 (5 0 -TGTCAGGTTGCGGGGGT AT-3 0 ). For the amplification of 18S rRNA, the following primers were used: 18S-F (5 0 -CCTGCGGCTTAATTT GACTC-3 0 ) and 18S-R (5 0 -CGCTGAGCCAGTCAGTG TAG-3 0 ). All PCR reactions were performed in duplicate. Standard curves for FasL, FADD and 18S rRNA were generated independently. The relative copy number of each sample was calculated according to the corresponding standard curve using RotorGene version 4.6 software. Normalization was performed in each sample by dividing the copy number of either FasL or FADD by that of 18SrRNA. The relative expression levels were calculated by arbitrarily designating the lowest normalized value to one.
In vivo transduction
Four groups (n ¼ 5) of 6-to 8-week-old CB-17 SCID mice (Animal Resource Centre, Perth, Australia) were subcutaneously injected with 2 Â 10 6 dGli36-SCID8 (derivative of dGli36 cells) cells. A total of 2 Â 10 6 TU of viral vectors was administered intratumorally. The tumor volume was measured and calculated using the formula: tumor volume (mm 3 ) ¼ 0.52 Â (width (mm 2 ) Â (length (mm)). 16 Animals in all the groups were killed after 19 days when the tumors in the control group were severely necrotic.
Statistical analysis
Data are presented throughout this study as means 7standard error of the mean (s.e.m.). Statistical significance in the in vitro experiments was evaluated by unpaired t-test, and Po0.05 was considered significant. In the in vivo experiments, statistical significance was evaluated by one-way ANOVA, and Po0.05 was considered significant. Figure 1b) or FADD (pC8-FADD, Figure 1d ). In addition, we have also generated the basic constructs, pIH8GalFasL ( Figure 1a ) and pIH8Gal-FADD (Figure 1c) , which contain the minimal cyclin A promoter driving the FasL gene and FADD gene, respectively. Further description of the cloning strategies can be found in the Materials and methods section.
Results

Construction of
Cell death induced by both FasL and FADD is regulated in a cell cycle-dependent manner To determine if apoptosis mediated by FasL gene expression could be restricted to proliferating cells, dGli36 human glioma cells were infected with pC8-FasL and the control vector, pIH8GaLFasL, at an MOI of 1.0. After 6 h of infection, the cells were replenished with fresh medium containing 10% FBS to induce proliferation or treated with medium containing 1% FBS with 50 ı`M of lovastatin to induce G 1 -arrest. Induction of G 1 -arrest was confirmed using FACS analysis, which decreased the percentage of S-phase cells from approximately 52.8-6.51% (data not shown). The percentage of apoptosis was determined in dGli36 cells infected with pC8-FasL in both proliferating and G 1 -arrested stage using trypan blue exclusion assay in triplicate. Approximately, 41.2% cell death was detected in proliferating dGli36 cells infected with pC8-FasL, which was 10-fold higher than that of the G 1 -arrested population (4.2%) (P ¼ 0.032; Figure 2a) . In contrast, cell death was not observed in both proliferating and G 1 -arrested populations infected with pIH8GalFasL. To correlate the level of protein expression with the degree of cell death induced by FasL overexpression, cellular extracts were harvested from FasL-transduced cells and analyzed using ELISA. FasL expression in the pC8-FasL-transduced proliferating population was fourfold higher than the corresponding G 1 -arrested cells (Figure 2b ). The slight increase in FasL expression observed in the G 1 -arrested population and the pIH8-GalFasL-infected cells could be due to the combined effect of serum and lovastatin, which has been reported to induce apoptosis in some glioma cells. 17, 18 Furthermore, using TUNEL assay, pyknotic nuclei were only evident in proliferating cells transduced with pC8-FasL but absent in G 1 -arrested populations (Figure 2c ). In comparison to pC8-FasL-transduced cells, no cell death could be detectable in either proliferating or G 1 -arrested cells that were infected with pIH8GaLFasL vectors. These results showed that cell death mediated by pC8-FasL is specific for proliferating cells, thus demonstrating that FasL expression can be activated upon cellular proliferation. Next, the level of cell death induced by pC8-FADD was also determined in dGli36 cells using a similar method as described earlier. In all, 22% cell death was observed in the proliferating population in comparison to 4% in the G 1 -arrested population (P ¼ 0.019; Figure 3a ). In contrast, minimal apoptosis was detected in both proliferating and G 1 -arrested cells infected with pIH8GalFADD (Figure 3a) . The level of FADD expression in pC8-FADD-transduced proliferating dGli36 cells was also found to be higher than that of the G 1 -arrested cells, with proliferating cells exhibiting a 15-fold higher level of FADD expression (Figure 3b ). Similar to FasL, TUNEL positive cells were only detectable in proliferating cells infected with pC8-FADD (Figure 3c ), while the G 1 -arrested cells and the control-infected cells did not exhibit any fluorescence. Collectively, these results suggest that FADD and FasL expression could be regulated in a proliferation-dependent manner using the cell cycleregulated HSV-1 amplicon vectors. In addition, we have also constructed pHGCX-CMV-FasL and pHGCX-CMV-FADD where pHGCX is the basic amplicon vector lacking cell cycle-regulatory elements. 1 Our results showed that either pC8-FasL or pC8-FADD could confer an enhanced apoptotic effect in proliferating cells versus G 1 -arrested cells (P ¼ 0.007 and 0.012, respectively). However, the level of apoptotic effect mediated by pHGCX-CMV-FasL or pHGCX-CMV-FADD was statistically insignificant between the proliferating cells and G 1 -arrested cells (P ¼ 0.0854 and 0.112, respectively). In addition, the percentage of cell viability in pC8-FasL transduced dGli36 cells was comparable to that of pHGCX-CMV-FasL (P ¼ 0.559). Similarly, apoptotic activities in pC8-FADD-transduced dGli36 cells were also comparable to pHGCX-CMV-FADD (P ¼ 0.304). Thus, CMV promoter gave no additional cytotoxic effect in comparison to the constructs with the cell cycleregulatory elements.
Coexpression of FasL-and FADD-enhanced apoptosis
Since the overexpression of FADD or FasL only induced approximately 20-45% cell death in dGli36 cells ( Figures  2 and 3) , we sought to investigate whether coexpression of FasL and FADD is able to enhance the apoptotic activity. To determine the combined effect of FasL and FADD, dGli36 cells were infected with (i) pC8-36, (ii) pC8-FasL, (iii) pC8-FADD and (iv) 1:1 ratio of pC8-FasL and pC8-FADD at an MOI of 1.0 for 6 h. The infected cells were either allowed to proliferate or induced to arrest in G 1 of apoptosis by 20% with respect to pC8-FasL alone and 30% with respect to pC8-FADD alone (Figure 4) . Cytotoxicity observed in these cotransduced proliferating cells was also significantly higher (60%, P ¼ 0.04) than the corresponding G 1 -arrested cells (10%). This result suggests that FasL and FADD might interact to bring about a greater apoptotic effect in vitro.
FasL and FADD genes delivery in vivo suppresses tumor growth The apoptotic effect of pC8-FasL and pC8-FADD was also examined in vivo. The injection regime was predetermined in vitro according to the kinetics of FasL (Figure 5a ) and FADD (Figure 5b ) expression at various time points following infection with either pC8-FasL or pC8-FADD. Hence, pC8-FasL and pC8-FADD viral vectors were administered every 10 and 3 days, respectively. The administration of the control vectors followed the injection regime of FasL, that is, every 10 days.
dGli36-SCID8 cells were used for the in vivo experiment because this cell line consistently forms subcutaneous tumor in immunodeficient SCID mice. Similar to dGli36 cells, this derivative is also sensitive to FasL-and FADDinduced apoptosis, and has more aggressive tumor growth kinetics in immunodeficient mice (data not shown). Tumor volume of 121 mm 3 (average of five animals) consistently formed at day three postimplantation of dGli36-SCID8 cells into the flanks of SCID mice. In an attempt to ensure an optimal ratio between therapeutic vectors against tumor cells, we chose to administer the viral vectors the next day following tumor cells implantation. Palpable tumors were injected with 2 Â 10 6 TU of (i) pC8-36, (ii) pC8-FasL and (iii) pC8-FADD viral vectors. To investigate the combined effect of FasL and FADD in vivo, dGli36 tumors were also injected with both pC8- pC8-FADD construct was significantly smaller than that in the control vector group (Po0.001 and Po0.01, respectively; Figure 5c ). In mice treated with pC8-FasL, the tumor volume ranged between 2 and 19 mm 3 , with two out of five animals completely devoid of any detectable tumor mass. The effect of pC8-FADD expression in dGli36-SCID8 tumor was comparatively weaker than pC8-FasL, with tumor volume ranging from 2 to 85 mm 3 , with two out of five mice tumor free. Interestingly, effective suppression of tumor growth was observed in all mice coinjected with pC8-FasL and pC8-FADD; all animals in this treatment group were tumor free (Figure 5c ). During the early stages of the experiment, we noticed that tumor mass in this group of mice was consistently smaller (range, approximately 0.77-4.21 mm 3 ) than any of the treatment groups, suggesting that coexpression of both FasL and FADD effectively enhanced the apoptotic index of the xenografts, thus preventing tumor growth. Although considerable differences were observed in the tumor volume among the treatment groups, this difference is considered as statistically insignificant. To confirm that overexpression of FasL and FADD resulted in the suppression of tumor growth observed in all the animals, real-time RT-PCR was performed on the dissected tumors (harvested at the end of the experiment from one extra mouse that contains palpable tumor) to quantitate the level of exogenous FasL and FADD mRNA expressions. All samples were normalized to that of 18S rRNA. The differential mRNA expressions were expressed as a ratio between tumors injected with therapeutic vectors and control tumors injected with the backbone vectors. As shown in Table 1 , the mRNA level of FasL in the tumor injected with pC8-FasL was five-fold higher than those injected with the control vector. Interestingly, coinfection of pC8-FADD and pC8-FasL resulted in a 20-fold increase in the FasL mRNA activities in comparison to the control tumor. Similarly, the level of FADD mRNA was also higher in tumors that were coinfected with FasL and FADD (2.2-fold higher than control) compared with FADD alone (0.62-fold higher than control). The level of FasL or FADD mRNA expression correlates with the suppression of tumor growth, such that the tumor volume in mice coinjected with FasL and FADD was the smallest, followed by pC8-FasL, pC8-FADD and lastly, the control vector. Taken together, these results demonstrated that therapeutic gene expression mediated by the cell cycle-regulated vector suppresses tumor formation in vivo.
Discussion
In this study, we incorporated the FasL and FADD genes into the cell cycle-regulated amplicon vector and demonstrated that the expression and function of these genes can be regulated according to the cell-cycling event.
The apoptotic-inducing activities of FADD and FasL were approximately 18-37% higher in proliferating cells in comparison to those in the G 1 -arrested cells (Figures 3a  and 2a) . Further analysis by flow cytometry showed that actively proliferating cells contained approximately 46% of S-phase cells (data not shown). In accordance with the number of cells undergoing S-phase and the observation that FasL expression appeared to induce a bystander effect on neighboring untransduced cells, we expected that the level of apoptosis would be at least 46% or even higher. However, the level of apoptosis induced in proliferating cells was less efficient indicating that mechanisms may exist to attenuate the effect of overexpression of these proteins within the cell. In addition, endogenous FasL and FADD proteins were detectable at low levels in dGli36 cells, suggesting that they may be needed for normal physiologic functioning of the cells. Therefore, other apoptosis-inducing genes with potentially higher cell apoptotic effects should be explored in the context of these viral vectors.
We observed an increase in the percentage of apoptosis in pC8-FADD-transduced dGli36 cells when compared to the control vector, thus indicating that dGli36 cells were sensitive to FADD-induced apoptosis. The apoptotic activity was augmented when both FasL and FADD were coexpressed, which was further examined in immunodeficient mice harboring subcutaneous dGli36-SCID8 glioma xenografts. We observed that two out of five animals injected with either pC8-FasL or pC8-FADD were completely devoid of tumor. These results indicated that FasL and FADD genes expression mediated by this cell cycle-regulated vector is able to suppress tumor growth in vivo. Complete regression of tumors was not observed possibly due to the following reasons: firstly, the expression patterns of FasL and FADD were determined in vitro, which might not truly represent the in vivo condition. Secondly, the expression of the therapeutic genes is strictly dependent on cell division. It is possible that the expression of FasL was not activated due to the absence of proliferating cells in the injected region. Often, the center of the tumors is composed of cells undergoing necrosis due to hypoxia and lack of nutrient associated with reduced vasculature from overcrowded cells. Taken together, our results suggested that the overexpression of FADD protein could interact with FasL to bring about an enhanced cell-killing effect. Alternately, the different genetic profile of glioma cell lines, with different levels of proapoptotic or antiapoptotic molecules, might play a role in the differential level of cell killings observed. Further studies are required to determine if the enhanced, restricted expression of FasL and FADD therapeutic proteins could confer a similar protective effect in mice bearing intracranial tumor cells since glioma cells are heterogeneous in nature. In summary, we have demonstrated the efficacies of our viral vectors using therapeutic genes such as FasL or FADD both in vitro and in vivo. The expression of these therapeutic genes is shown to be tightly regulated by the proliferation event. A safety evaluation of the backbone pC8-36 amplicon viral vectors has also been performed in the brains of BALB/c mice using Ad-GFP and saline as positive and negative controls, respectively. Immunohistochemistry staining was positive for CD4, CD8 (markers for T lymphocytes) and CD11b (marker for microglial infiltration) in all three groups of animals 1 day postinfection, presumably due to the transient disruption of the blood-brain barrier. However, the expression levels returned to normal after four days postinjection. In contrast, adverse immunological response was persistent in mice injected with Ad-GFP (data not shown). Therefore, these vectors are safe and could be employed as an adjuvant therapy to prevent residual tumor cells from causing further damage to surrounding normal cells. Furthermore, we have also shown that multiple therapeutic modalities could be employed as a promising tool for the treatment of highly heterogeneous tumors.
